Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | TK1 | P04183 | 2/20 | 0.48 |
| ▸ | PNP | P00491 | 3/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ADCY5 | O95622 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbovir SCHEMBL19237554 | 1.00 | NR1I2 (0.56) | NR1I2ALBPDE4DADORA3HPRT1 | |
| Carbovir SCHEMBL8447674 | 1.00 | NR1I2 (0.56) | NR1I2ALBPDE4DADORA3HPRT1 | |
| Carbovir SCHEMBL9867194 | 1.00 | NR1I2 (0.56) | NR1I2ALBPDE4DADORA3HPRT1 | |
| Carbovir SCHEMBL180360 | 1.00 | NR1I2 (0.56) | NR1I2ALBPDE4DADORA3HPRT1 | |
| Carbovir SCHEMBL30552224 | 0.91 | ADORA3 (0.51) | NR1I2ALBPDE4DADORA3HPRT1 | |
| SCHEMBL14015633 | 0.88 | BCHE (0.52) | NR1I2ALBPDE4DADORA3HPRT1 | |
| SCHEMBL9685090 | 0.88 | BCHE (0.52) | NR1I2ALBPDE4DADORA3HPRT1 | |
| SCHEMBL9704154 | 0.86 | BCHE (0.57) | ADORA3HPRT1BCHEPNPBLM | |
| SCHEMBL23587713 | 0.86 | NR1I2 (0.56) | NR1I2ALBPDE4DADORA3HPRT1 | |
| SCHEMBL6554844 | 0.86 | NR1I2 (0.56) | NR1I2ALBPDE4DADORA3HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | claimed |
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | claimed |
| WO-2021191417-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-09-30 | — | — | WO | claimed |
| US-20070025964-A1 | HIV-1 mutations selected for by beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine | EMORY UNIVERSITY | 2007-02-01 | — | — | US | claimed |
| EP-1731155-A2 | Beta-D-2', 3' -Didehydro-2',3' -Dideoxy-5-Fluorocydine for use in the treatment of HIV infections | EMORY UNIVERSITY (US) | 2006-12-13 | — | — | EP | claimed |
| EP-0805683-B1 | 5-FLUORO-2',3'-UNSATURATED-PYRIMIDINE NUCLEOSIDES | UNIV EMORY (US) | 2005-12-28 | — | — | EP | claimed |
| US-20040082552-A1 | HIV-1 mutations selected for by beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine | EMORY UNIVERSITY | 2004-04-29 | — | — | US | claimed |
| JP-2002535278-A | — | — | 2002-10-22 | — | — | JP | claimed |
| CN-1337880-A | HIV-1 mutations selected by beta-2 ', 3' -didehydro-2 ', 3' -dideoxy-5-fluorocytidine | UNIV EMORY (US) | 2002-02-27 | — | — | CN | claimed |
| EP-1143976-A2 | BETA-D-2', 3' -DIDEHYDRO-2', 3' -DIDEOXY-5-FLUOROCYTIDINE FOR USE IN THE TREATMENT OF HIV INFECTIONS | EMORY UNIVERSITY (US) | 2001-10-17 | — | — | EP | claimed |
| US-6232300-B1 | ADMINISTERING AS HEPATITIS B VIRICIDE | EMORY UNIVERSITY | 2001-05-15 | — | — | US | claimed |
| WO-2000043014-A2 | BETA-D-2',3'-DIDEHYDRO-2',3'-DIDEOXY-5-FLUOROCYTIDINE FOR USE IN THE TREATMENT OF HIV INFECTIONS | EMORY UNIVERSITY (US) | 2000-07-27 | — | — | WO | claimed |
| EP-0361831-A1 | Antiviral nucleoside combination | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-04 | — | — | EP | claimed |
| JP-2129125-A | — | — | None | — | — | JP | disclosed |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | disclosed |
| JP-H02129125-A | ANTIVIRAL NUCLEOSIDE-COMBINED AGENT | WELLCOME FOUND LTD:THE | 1990-05-17 | — | — | JP | disclosed |
| EP-0366385-A1 | Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-05-02 | — | — | EP | disclosed |
| EP-0361831-A1 | Antiviral nucleoside combination | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-04 | — | — | EP | disclosed |
| EP-0349242-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | ACE, ACE2, PNP | NR1I2 2250/4885ALB 3707/4885PDE4D 483/4885 |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SNCA, PARK7, PRNP | NR1I2 3988/4885ALB 2382/4885PDE4D 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.